CancerFax
Patient Success Story

Hasan

After his gastric DLBCL returned following an initial complete response, Hasan travelled from Iran to Beijing to access CD19 CAR-T cell therapy.

68 years oldRelapsed Gastric DLBCLCD19 CAR-T Cell TherapyTreated in ChinaReceived CD19 CAR-T Therapy
photo_camera
Patient Photo
Place patient image here
(with documented family consent)
verified_userShared with Family Consent
favoritePatient Success Story

Hasan, a Patient with Relapsed Gastric DLBCL from Iran

After achieving a complete response to first-line treatment in Iran, Hasan's gastric lymphoma returned and progressed. He travelled to Lu Daopei Hospital in Beijing to access CD19 CAR-T cell therapy.
person68 years old
biotechRelapsed Gastric DLBCL
scienceCD19 CAR-T Cell Therapy
flight_takeoffTreated in China
check_circleReceived CD19 CAR-T Therapy
forum

Why the Family Contacted CancerFax

Hasan's family knew that CAR-T cell therapy existed for relapsed lymphoma, but they did not know where it was genuinely available for an international patient, whether Hasan would qualify, or how to arrange treatment abroad while his disease was progressing. The questions were medical, logistical, and time-sensitive all at once.

search
Which centres treat relapsed DLBCL with CD19 CAR-T?

CAR-T programmes vary widely in depth and experience. Identifying a centre with a strong track record in relapsed B-cell lymphoma required specialist knowledge.

science
Would Hasan be a suitable candidate for CAR-T?

At 68, with relapsed disease and possible kidney involvement, eligibility needed careful evaluation by an experienced cell-therapy team.

translate
How does a patient from Iran arrange treatment in China?

Document translation, visa support, hospital communication, and travel coordination all needed to come together quickly and reliably.

"We had seen his scans turn clear once, and then the lymphoma came back. We did not want to lose time. We just needed someone to tell us what was actually possible."β€” Hasan's family

support_agent

How CancerFax Helped

CancerFax reviewed Hasan's medical records, organised them into a structured case file, and worked to connect the family with a centre experienced in CD19 CAR-T cell therapy for relapsed B-cell lymphoma. Throughout the process, communication and logistics were coordinated so the family could focus on Hasan.

folder_shared
Case File Organisation

PET/CT reports, endoscopy and biopsy findings, immunohistochemistry, and the relapse imaging were compiled into a clear case file for specialist review.

search
Hospital & Specialist Match

CancerFax helped identify Lu Daopei Hospital in Beijing, a centre with significant experience in CAR-T cell therapy for B-cell lymphoma.

translate
Communication & Translation

Clinical documents were prepared and translated, and communication between the family and the hospital team was managed throughout the evaluation.

flight_takeoff
Travel & Logistics Support

Visa documentation, travel guidance, and on-the-ground coordination were arranged for Hasan and his accompanying family member.

CancerFax did not provide clinical opinions or make treatment decisions. All clinical decisions, including eligibility and the treatment plan, were made by the oncology and cell-therapy team at Lu Daopei Hospital, Beijing, based on a full medical evaluation of Hasan's case.
timeline

Hasan's Treatment Journey

Key steps from diagnosis to treatment and beyond.

Step 1
Step 1 β€” Initial Diagnosis (2021)

An FDG PET/CT scan showed a large active mass in the stomach and duodenum with liver and abdominal lymph node involvement. Endoscopic biopsy and immunohistochemistry confirmed diffuse large B-cell lymphoma, non-germinal center type.

Step 2
Step 2 β€” First-Line Treatment and Complete Response (2021 to early 2022)

Hasan received first-line treatment in Iran. A follow-up PET/CT scan in early 2022 showed an excellent complete metabolic response, with a Deauville score of 1 and resolution of the gastric mass and abdominal lymph nodes.

Step 3
Step 3 β€” Relapse and Disease Progression (early 2023)

A comparison PET/CT scan showed progressive disease, with renewed activity in the gastric antrum and new or enlarging lymph nodes in the chest and abdomen.

Step 4
Step 4 β€” Advancing Disease and Limited Local Options (mid 2023)

Imaging showed multiple enlarged para-aortic and peripancreatic lymph nodes, some with central necrosis. Blood tests pointed to reduced kidney function and a microcytic anemia pattern. The family began exploring advanced treatment options abroad.

Step 5
Step 5 β€” Contact with CancerFax and Case Review

The family reached out to CancerFax. The medical records were reviewed and organised, and CD19 CAR-T cell therapy at an experienced centre was identified as a possible path worth evaluating.

Step 6
Step 6 β€” Travel to Beijing and Evaluation at Lu Daopei Hospital

Hasan travelled from Iran to Lu Daopei Hospital in Beijing. The cell-therapy team carried out its own evaluation of his case, fitness, and suitability for CAR-T cell therapy.

Step 7
Step 7 β€” CD19 CAR-T Cell Therapy

Following the hospital's assessment, Hasan proceeded with CD19 CAR-T cell therapy. The treatment process typically involves collecting the patient's T-cells, engineering them, and reinfusing them after a short conditioning regimen.

Response assessment is ongoing. This section will be updated once confirmed results are available.

info
An important reminder

Every patient's treatment plan is individual. The pathway above describes this specific case β€” not a blueprint for others. Suitability for each treatment is determined by the treating clinical team based on each patient's individual clinical situation.

favorite

Where Hasan Is Today

Hasan completed CD19 CAR-T cell therapy at Lu Daopei Hospital in Beijing. As with any patient who undergoes cell therapy, he is being monitored closely by the treating team during the early recovery and response-assessment period.

Formal response assessment, including follow-up imaging, guides the next steps in his care. CancerFax remains available to the family for coordination and follow-up support as needed.

β€œ"Reaching this point felt out of reach when we started. Having someone walk us through each step made a frightening situation manageable."”— Hasan's family

school

What Other Families Can Learn

Hasan's journey offers a few practical takeaways for families facing relapsed lymphoma and weighing advanced treatment options abroad.

search
A complete response is not always the end of the story

Lymphoma that clears completely can still relapse later. Acting promptly when disease returns helps keep more treatment options open.

biotech
Confirm the full pathology picture

Recommended tests such as FISH for BCL2, BCL6, and C-MYC can change how a lymphoma is classified and treated. Completing them supports better decisions.

timer
Time and fitness matter in relapsed disease

Exploring advanced therapies like CAR-T while a patient is still well enough to travel and undergo treatment is important.

translate
Cross-border care is manageable with the right support

Translation, documentation, and hospital communication can feel overwhelming. Coordinated navigation removes much of that burden.

How CancerFax Can Support Your Family

If you or a loved one is facing a complex or relapsed cancer diagnosis β€” or you have been told that local options are limited β€” CancerFax can help you understand what may be possible and how to access it.

Related on CancerFax

quiz

Frequently Asked Questions

Yes. CancerFax can review medical reports, identify hospitals and specialists experienced in relapsed and refractory B-cell lymphoma, and help coordinate access to advanced treatment options such as CD19 CAR-T cell therapy. Contact our team to share medical reports for review.

Yes. Several centres in China, including Lu Daopei Hospital in Beijing, treat international patients with CD19 CAR-T cell therapy for eligible relapsed or refractory B-cell lymphomas. Eligibility is determined by the treating cell-therapy team after a full medical evaluation. CancerFax can help families prepare records and navigate access.

Age alone does not rule out CAR-T cell therapy. Suitability depends on overall fitness, organ function, and the specifics of the disease, and is assessed individually by the treating team. A thorough evaluation is essential before any treatment decision is made.

No. CancerFax is a patient navigation and treatment access platform. We help patients understand their options, identify suitable centres, prepare case files, and coordinate logistics. All clinical decisions are made by qualified medical specialists at the treating institution.

Yes. We encourage families to share medical reports early so our team can review the case and provide a clearer picture of what treatment may be possible β€” before any travel commitment is made. There is no cost for this initial review.

infoImportant Disclaimer

This patient story reflects an individual treatment journey. Outcomes vary from patient to patient. The information on this page should not be taken as medical advice or a guarantee of similar results. Treatment suitability depends on diagnosis, disease status, prior therapy, molecular findings, overall health, and specialist medical evaluation. Names and identifying details may be modified to protect patient privacy. All clinical decisions must be made in consultation with a qualified, licensed physician with access to the patient's complete medical information.

Need Help Understanding the Next Step?

If you or a loved one is facing a complex cancer diagnosis, relapse, or limited treatment options, CancerFax can help you organise the case, explore relevant hospitals and doctors, and understand whether advanced treatment or clinical trial pathways may be appropriate.

Β© CancerFax Β· Patient navigation and coordination platform. CancerFax is not a medical institution and does not provide medical treatment. All clinical care is provided by independent licensed physicians and hospitals. Patient names and identifying details are modified or anonymised where required to protect privacy. Story shared with documented family consent.